Antibody Drug Conjugates (eBook)

Design, Discovery, and Development
Artikelnummer: 978-3-031-89319-3
Einband: PDF
Verfügbarkeit: Download, sofort verfügbar (Link per E-Mail)
CHF 153.50
decrease increase

This volume ¿provides a comprehensive recapitulation of structure-activity relationship (SAR) from a mechanism of action point of view for this unique therapeutic modality, in a largely disease agnostic manner. From a disease biology and pharmacology perspective, the cellular target and drug-conjugate selection, considerations on liker -chemistry and -antibody ratio, and formulation science and technology, to get from bench to bedside (i.e. from a laboratory to the systemic circulation in a patient). The book also provides an understanding around target binding and drug/"payload" release mechanisms. Furthermore, pharmacokinetic and safety pharmacological aspects from a regulatory and clinical perspective are discussed, along with current chemistry, manufacturing, controls guidance and emerging novel delivery devices or technologies.

The key differentiation in Antibody Drug Conjugates is the clinical and development discussion, that offers pragmatic considerations in medical product development, IP, regulatory considerations, among others. Furthermore, we discuss the topic as a platform, in a disease agnostic manner.

This volume ¿provides a comprehensive recapitulation of structure-activity relationship (SAR) from a mechanism of action point of view for this unique therapeutic modality, in a largely disease agnostic manner. From a disease biology and pharmacology perspective, the cellular target and drug-conjugate selection, considerations on liker -chemistry and -antibody ratio, and formulation science and technology, to get from bench to bedside (i.e. from a laboratory to the systemic circulation in a patient). The book also provides an understanding around target binding and drug/"payload" release mechanisms. Furthermore, pharmacokinetic and safety pharmacological aspects from a regulatory and clinical perspective are discussed, along with current chemistry, manufacturing, controls guidance and emerging novel delivery devices or technologies.

The key differentiation in Antibody Drug Conjugates is the clinical and development discussion, that offers pragmatic considerations in medical product development, IP, regulatory considerations, among others. Furthermore, we discuss the topic as a platform, in a disease agnostic manner.

Schreiben Sie Ihre eigene Bewertung
  • Nur registrierte Benutzer können Produkte bewerten
*
*
Schlecht
Sehr gut
*
*
*
*
VerlagSpringer Nature Switzerland
EinbandPDF
Erscheinungsjahr2026
Seitenangabe232 S.
AusgabekennzeichenEnglisch
AbbildungenVIII, 232 p. 35 illus., 24 illus. in color.
Masse12'264 KB
PlattformPDF
ReiheAAPS Advances in the Pharmaceutical Sciences Series; Biomedical and Life Sciences; Biomedical and Life Sciences
AutorGukasyan, Hovhannes J. (Hrsg.) / Kulkarni, Ashutosh (Hrsg.)

Alle Bände der Reihe "AAPS Advances in the Pharmaceutical Sciences Series; Biomedical and Life Sciences; Biomedical and Life Sciences (R0)"

Weitere Titel von Hovhannes J. (Hrsg.) Gukasyan

Produktbewertungen
Nur registrierte Benutzer können Produkte bewerten